VERIMATRIX
5.6.2019 07:02:05 CEST | Business Wire | Press release
Verimatrix, the leader in redefining the standard for connected devices and services with an innovative combination of security and data analytics, and IPTV technology company Ocilion today announced two large Austrian operators as their latest customers. kabelplus and Salzburg AG have each selected on-premise IPTV solutions from Ocilion that are secured by Verimatrix, enabling more flexible and future-proof video delivery models.
Both operators opted independently for on-premise deployments hosted in their distinctive infrastructures, optimally suiting larger volumes of subscribers using Ocilion’s new homogenous P400 family of 4K set-top boxes (STBs), which combines innovation, design, functionality and efficiency. The advanced and adaptable technology offers the flexibility needed to support various delivery models, whether hybrid, FTTH or OTT, while the integrated Verimatrix client supports digital rights management (DRM) for IP, IP/DVB-C and OTT.
“kabelplus and Salzburg AG came to us with unique challenges and needs that will grow and evolve as consumer demands and security requirements continue to rapidly shift,” said Hans Kühberger, CEO of Ocilion. “We are very pleased to fulfil their demands for increasingly sophisticated modern and high-end IPTV services with our future-proof on-premise solution, including our new P400 family and resolve complex security requirements in partnership with Verimatrix.”
The decision for kabelplus, the largest cable network provider in Lower Austria and Burgenland, to launch its own IPTV product resulted from the need to extend its portfolio for its HFC network with extra products and services, and it came during the middle of a FTTH expansion and rollout. In need of a competitive edge to reinforce its position as a top service provider, kabelplus saw the Ocilion-Verimatrix partnership as the perfect fit to elevate its product portfolio with new premium features and bundling options.
When live-only DVB-C delivery was no longer enough to support Salzburg AG’s consumer demands, the Salzburg energy, transport and telecommunications provider turned to Ocilion and Verimatrix to set the foundation for it to be able to offer premium service enhancements and maximize upselling opportunities with long-term adaptability.
With these deployments, the Austrian operators are also laying the foundation for secure UHD ecosystems with OcilionsP400 line of STBs having officially received the Verimatrix 4.0 Ultra Security certification. This certification emphasizes their readiness to fully meet UHD security requirements, ensuring that they meet UHD content guidelines set by MovieLabs’ Specifications for Next Generation Video and Enhanced Content Protection.
“Achieving Ultra Security certification means that Ocilion’s advanced STBs are trusted to deliver premium content to kabelplus and Salzburg AG consumers at the highest quality possible and in accordance with the strongest security requirements specified by premium rights holders,” commented Verimatrix COO Steve Oetegenn. “Ultimately, the combined strengths of Ocilion and Verimatrix presents a formidable barrier against piracy in a form that can be updated readily to ensure these operators are able to keep pace with the evolving threat landscape.”
About Ocilion
Ocilion is a software company, providing individual end-to-end IPTV platforms to network providers in German-speaking Europe (Germany, Austria, Switzerland & Liechtenstein) since 2004. The white labelled IPTV platform is suited for all network topologies (HFC, FTTH, VDSL, OTT) and contains content, services, premium TV features (Replay, PVR, VoD), a full family of pre-integrated 4K set-top boxes and apps (smartphone, tablet, Apple TV, Amazon Fire TV). Operators can choose between on-premise systems (hosted in their distinctive infrastructure) and a rental option hosted by Ocilion (optimised for medium-sized carriers). Since 2009, the IPTV specialist started IPTV building solutions for hotels, hospitals, ships, corporate buildings and other projects (iptv500 product). For more information, visit www.ocilion.com .
About Inside Secure/Verimatrix
Inside Secure/Verimatrix (Euronext Paris – INSD) is redefining the standard for connected devices and services with an innovative combination of security and data analytics that maximizes revenues, protects reputations and enables growth. The company serves a range of industries and markets, including entertainment, mobile, computer networks and internet of things (IoT). The company offers easy-to-use software solutions, cloud services and silicon IP that provides unparalleled security and business intelligence. With more than 24 years of experience and a solid reputation, Inside Secure/Verimatrix protects customers’ most valuable content, transactions, applications, and communications. With 18 office locations in 12 countries supporting more than 1,200 customers, the company is uniquely positioned to secure and enable the connected future. For more information, visit www.insidesecure.com and www.verimatrix.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190604006167/en/
Contact:
Kelly Foster, Verimatrix +1 619 224 1261 kfoster@verimatrix.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom